TBA (last known deadline was December 3, 2012)
JDRF invites applications from single investigators or teams of investigators to develop and conduct studies towards the goal of discovering and validating druggable targets and biologic factors for promoting pancreatic beta cell regeneration, health and survival in type 1 diabetes.
The purpose of this RFA is to invite outstanding proposals to characterize and validate novel drug targets or biologic factors that will promote regeneration and survival of functional beta cell mass. Proposed studies should provide a basis for translation to a future drug discovery platform. In addition, most of the molecular insights into regulation of beta cell mass come from studies in animal models, and relevance to human beta cell regeneration and function is a top priority.